Iloprost Zentiva (Iloprost)

Iloprost is a synthetic analogue of prostacyclin that activates prostacyclin (IP) receptors on vascular smooth‑muscle cells. This activation raises cyclic AMP levels, causing the muscles to relax, which dilates the pulmonary arteries and inhibits platelet aggregation, thereby lowering pulmonary arterial pressure and enhancing tissue perfusion.

The dose of Iloprost Zentiva is individualized by the prescribing healthcare professional based on the patient’s condition, response, and tolerance. The prescriber determines the appropriate inhalation volume, frequency, and duration, and patients should follow the specific instructions provided by their clinician.

The safety of Iloprost Zentiva in pregnancy or while breastfeeding has not been definitively established. Healthcare providers should weigh the potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To request Iloprost Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iloprost belongs to the prostacyclin class, offering direct vasodilation via inhalation, which can provide rapid symptom relief. Compared with oral endothelin‑receptor antagonists or phosphodiesterase‑5 inhibitors, iloprost delivers targeted pulmonary effects with fewer systemic side effects, but requires patient training for inhalation and may cause local respiratory irritation.

Iloprost Zentiva should be stored at room temperature, below 25 °C, in its original packaging. Keep the solution away from moisture, direct sunlight, and extreme temperatures. Do not freeze the product, and ensure the inhalation device is clean and maintained according to the manufacturer’s guidelines.

Iloprost Zentiva is delivered as an inhalation solution using a specialized nebulizer. The patient inhales the medication through the mouthpiece for the prescribed duration, typically several times per day. Proper technique and device cleaning are essential to ensure accurate dosing and optimal therapeutic effect.

Serious risks include severe hypotension, pulmonary edema, life‑threatening bronchospasm, significant bleeding, and rare cardiac arrhythmias. Patients should be monitored closely for sudden drops in blood pressure, worsening respiratory symptoms, or signs of bleeding, and any concerning events should prompt immediate medical evaluation.

Iloprost Zentiva is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, those with active bleeding disorders, severe uncontrolled hypotension, or recent major cardiovascular events. Caution is also advised for individuals with severe asthma, COPD, or other conditions that may predispose them to bronchospasm.